Hansa Biopharma announces positive topline data from the imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation

Data readout demonstrates a significantly superior capacity of imlifidase to rapidly reduce levels of donor-specific antibodies (DSAs) compared to plasma...

Related Keywords

Germany ,Sweden ,Australia ,Austria ,United States ,Stockholm ,France ,Hansa Biopharma ,Los Angeles ,Klaus Sindahl ,Christian Kjellman ,Adult Nephrology At Cedars Sinai Medical Center ,Division Of Pediatric ,Nasdaq Stockholm ,Stanley Jordan ,Principal Investigator ,Adult Nephrology ,Cedars Sinai Medical Center ,Chief Scientific Officer ,